• KOL
    • Breast Cancer
    • Qiao Li
    • Qiao Li: Influence Statistics

      Qiao Li

      Qiao Li

      National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; | ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Qiao Li:Expert Impact

      Concepts for whichQiao Lihas direct influence:Breast cancer,Metastatic breast,Negative breast,Metastatic breast cancer,Tumor heterogeneity,Chinese patients,Neoadjuvant therapy,Neoadjuvant chemotherapy.

      Qiao Li:KOL impact

      Concepts related to the work of other authors for whichfor which Qiao Li has influence:Breast cancer,Tumor dna,Liquid biopsy,Tp53 mutations,Neoadjuvant chemotherapy,Premenopausal women,Pyrotinib treatment.

      KOL Resume for Qiao Li

      Year
      2022

      National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;

      2021

      Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, NO.17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China

      2020

      Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

      2019

      National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.

      2018

      Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China

      2017

      Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

      2016

      From the Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Panjiayuannanli, Chaoyang District, Beijing, China.

      2015

      From the Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

      Peking Union Medical College Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences Beijing China

      2014

      Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

      2013

      Department of Medical Oncology, Cancer Hospital (Institute), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

      2010

      Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Qiao Li is among the top experts in the world.
      Concept World rank
      pyrotinib day #4
      pyrotinib adverse #4
      480 pharmacokinetic #4
      pyrotinib exposure #4
      pyrotinib administered #4
      pyrotinib maximum #4
      480 pyrotinib #4
      400 diarrhea #4
      38 oral ulceration #4
      day pyrotinib #4
      pyrotinib tolerated #4
      methods pyrotinib #4
      diarrhea doselimiting toxicity #5
      biomarkers pyrotinib #5
      analysis pyrotinib #6
      tolerability pyrotinib #7
      777 nonher2positive patients #9
      262 her2positive patients #9
      her2zero her2low groups #9
      status landmark analysis #9
      diarrhea pharmacokinetic #9
      metastatic tnbc anthracyclines #10
      adjuvant 115 #11
      ugt1a4 rs869283 #11
      patients ugt1a4 rs869283 #11
      rs869283 #11
      atg5 rs473543 #11
      tor chinese #11
      p0000 retreatment #11
      treatment her2mbc #11
      adjuvant tor #11
      10 c100c genotype #11
      progression ttp survival #11
      ugt1a4 clinical #11
      rs869283 genotype #11
      trastuzumabbased regimens metaanalysis #11
      findings genetic tamoxifen #11
      association rs869283 genotype #11
      115 tor #11
      statistical significance ttp #11
      ugt1a4 rs869283 genotype #11
      trial pyrotinib #11
      polymorphism rs869283 #11
      rs869283 genotype dfs #11
      tor option #11
      tamoxifen option #11
      tor 115 #11
      china toremifene #11
      trastuzumab treatment her2mbc #11
      adjuvant treatment genotype #11
      Sign-in to see all concepts, it's free!

      Prominent publications by Qiao Li

      KOL-Index: 12199

      BackgroundEpithelial–mesenchymal transition (EMT) is implicated in the metastatic process and presents a challenge to epithelial cell adhesion molecule-based detection of circulating tumor cells (CTCs), which have been demonstrated to be a prognostic indicator in metastatic breast cancer. Although evidence has indicated that heterogeneity of CTCs based on EMT markers is associated with disease progression, no standard recommendations have been established for clinical practice. This ...

      Known for Mesenchymal Transition | Breast Cancer | Circulating Tumor | Detection Based | Epithelial Ctcs
      KOL-Index: 10527

      Purpose This phase I study assessed the safety, tolerability, pharmacokinetics, antitumor activity, and predictive biomarkers of pyrotinib, an irreversible pan-ErbB inhibitor, in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Patients and Methods Pyrotinib was administered continuously, orally, once per day to patients who did not have prior exposure to tyrosine kinase inhibitors of HER2. Planned dose escalation was 80, 160, 240, 320, ...

      Known for Patients Pyrotinib | Metastatic Breast | Tumor Dna | Tyrosine Kinase | Growth Factor
      KOL-Index: 9387

      PURPOSE: This phase I study assessed the safety, tolerability, MTD, pharmacokinetics, antitumor activity, and predictive biomarkers of pyrotinib, an irreversible pan-ErbB inhibitor, in combination with capecitabine in patients with HER2-positive metastatic breast cancer (MBC).

      PATIENTS AND METHODS: Patients received oral pyrotinib 160 mg, 240 mg, 320 mg, or 400 mg once daily continually plus capecitabine 1,000 mg/m2 twice daily on days 1 to 14 of a 21-day cycle. Pharmacokinetic blood ...

      Known for Metastatic Breast | Pyrotinib Combination | Antitumor Activity | Predictive Biomarkers | Patients Her2
      KOL-Index: 9115

      BACKGROUND: Cisplatin is an effective agent for triple-negative breast cancer (TNBC) and synergistic activity between cisplatin and capecitabine has been demonstrated by in vitro and in vivo studies. This study was designed as a prospective clinical trial to evaluate the efficacy and safety of capecitabine plus cisplatin (XP) regimen in metastatic TNBC patients pretreated with anthracyclines and taxanes.

      PATIENTS AND METHODS: Thirty-three patients with metastatic TNBC who had ...

      Known for Metastatic Triple | Anthracyclines Taxanes | Capecitabine Cisplatin | Negative Breast | 21day Cycle
      KOL-Index: 8711

      AIMS: This phase II study prospectively evaluated the feasibility of vinorelbine in combination with capecitabine in Chinese patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes.

      METHODS: Vinorelbine (25 mg/m(2) intravenous infusion on days 1 and 8) and capecitabine (1,000 mg/m(2) b.i.d., days 1-14) were administered to eligible MBC patients previously treated with anthracyclines and taxanes every 3 weeks for up to 6 cycles, until disease progression or ...

      Known for Chinese Patients | Metastatic Breast Cancer | Vinorelbine Capecitabine | 6 Cycles | Combination Therapy
      KOL-Index: 7659

      Tumor heterogeneity was associated with treatment outcome of metastatic cancers but few studies have examined whether tumor heterogeneity in circulating tumor DNA (ctDNA) can be used to predict treatment outcome. ctDNA analysis was performed in 37 HER2-positive metastatic breast cancer patients treated with pyrotinib. Patients with high tumor heterogeneity had significantly worse PFS outcomes, with a median PFS of 30.0 weeks vs. 60.0 weeks for patients with low tumor heterogeneity ...

      Known for Tumor Heterogeneity | Metastatic Breast Cancer | Therapeutic Response | Median Pfs | Hazard Ratio
      KOL-Index: 7497

      Toremifene (TOR) is a valid and safe alternative to tamoxifen (TAM) for adjuvant endocrine therapy in breast cancer patients with a metabolic pathway that differs from that of TAM. TOR might have a therapeutic advantage in certain subgroups of patients, such as Chinese women with the CYP2D6 *10 (c.100C > T) T/T genotype, who would get less benefit when receiving adjuvant TAM treatment. A total of 230 breast cancer patients who received adjuvant TAM (n = 115) or TOR (n = 115) at the ...

      Known for Breast Cancer | Toremifene Tamoxifen | Tor Treatment | Diseasefree Survival | Adjuvant Endocrine Therapy
      KOL-Index: 7075

      The aim of the study was to determine the predictive role of breast cancer subtypes in the efficacy and prognosis of neoadjuvant chemotherapy (NCT) regimens combining taxanes and anthracyclines.Data from 240 patients with breast cancer who received surgery after 4 to 6 weeks of NCT were retrospectively analyzed. The patients were classified into luminal A, luminal B, HER2 overexpression, and triple negative breast cancer (TNBC) as well as low Ki67 (≤ 14%) and high Ki67 (> 14%) expression ...

      Known for Neoadjuvant Chemotherapy | Ki67 Expression | Breast Cancer | Molecular Subtypes | Patients Luminal
      KOL-Index: 7011

      BACKGROUND: Most studies utilizing circulating tumor DNA (ctDNA) to monitor disease interrogated only one or a few genes and failed to develop workable criteria to inform clinical practice. We evaluated the feasibility of detecting resistance to anti-HER2 therapy by serial gene-panel ctDNA sequencing.

      RESULTS: Primary therapeutic resistance was identified in 6 out of 14 patients with events of progressive disease. For this subset comparison of pre- and post-treatment ctDNA assay results ...

      Known for Metastatic Breast | Tumor Dna | Her2 Amplification | Cancer Treated | Resistance Neoplasm
      KOL-Index: 6959

      Variants of the CYP2D6 gene may lead to a poor prognosis of tamoxifen (TAM)-treated patients. Our study validated the association between the CYP2D6 genotype and outcomes of patients receiving TAM in adjuvant endocrine therapy. A total of 778 breast cancer patients who received adjuvant TAM (n = 325) or aromatase inhibitors (AIs) (n = 453) at the National Cancer Center were analyzed. Nine single nucleotide polymorphisms (SNPs) in the CYP2D6 gene were selected from online databases. The ...

      Known for Adjuvant Endocrine Therapy | Cyp2d6 Polymorphisms | Breast Cancer Patients | Diseasefree Survival | Dfs Total
      KOL-Index: 6119

      BACKGROUND: There is a lack of prognostic models predicting the overall survival (OS) of advanced breast cancer (ABC) patients in China.

      METHODS: Data from the China National Cancer Center database that recorded 4039 patients diagnosed with breast cancer between 1987 and 2019 were extracted and a total of 2263 ABC participants were enrolled in this study, which were further randomized 3:1 and divided into training (n = 1706) and validation (n = 557) groups. The nomogram was built based ...

      Known for Breast Cancer | Abc Patients | Predicting Survival | Training Validation | Independent Predictors
      KOL-Index: 5325

      PurposeThe Chinese bridging study PUFFIN (NCT02896855) aimed to assess consistency of efficacy with CLEOPATRA (NCT00567190), investigating pertuzumab with trastuzumab and docetaxel versus placebo, trastuzumab, and docetaxel in patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer.MethodsPatients were randomized 1:1, stratified by visceral/non-visceral disease and hormone receptor status. The primary endpoint was investigator-assessed ...

      Known for Pertuzumab Trastuzumab | Metastatic Breast | Positive Locally | Primary Endpoint | Median Pfs
      KOL-Index: 4948

      BackgroundBreast cancer is a global problem, and a large number of new cases are diagnosed every year. Capecitabine is effective in patients with metastatic breast cancer (MBC). Hand-foot syndrome (HFS) is a common adverse effect of capecitabine. In this study, we investigated the association between single nucleotide polymorphisms (SNPs) in genes involved in capecitabine metabolism pathways and capecitabine-induced HFS in Chinese patients with MBC to identify some predictive genetic ...

      Known for Hfs Tyms | Induced Hand | Foot Syndrome | Thymidylate Synthase | Antimetabolites Antineoplastic
      KOL-Index: 4558

      The risk factors for morbidity and mortality in patients with breast cancer liver metastases (BCLM) upon initial metastatic breast cancer (MBC) diagnosis have not been adequately identified in Han population. Data of 3,161 female patients who were initially diagnosed with MBC from December 1991 to September 2019 and treated in the China National Cancer Center were extracted and a total of 2,263 MBC patients were included in our study, among which 550 patients had liver metastases. ...

      Known for Bclm Patients | Cancer Diagnosis | Metastatic Breast | Lung Metastases | Hormone Receptor

      Key People For Breast Cancer

      Top KOLs in the world
      #1
      Ahmedin M Jemal
      united states breast cancer addis ababa
      #2
      Gabriel N Hortobagyi
      breast cancer neoadjuvant chemotherapy estrogen receptors
      #3
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      #4
      Charles M Perou
      breast cancer gene expression intrinsic subtypes
      #5
      Freddie Ian Bray
      cancer incidence nordic countries mortality rates
      #6
      Jacques Ferlay
      cancer incidence global burden latin america

      National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; | Department of Medical Oncology, National Cancer Center/National Clinical Rese

    Download on the App StoreGet it on Google Play

    Copyright © 2023 KOL - Key Opinion Leaders, LLC.

    KOL does not provide medical advice, diagnosis or treatment.